Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Virology. 2019 Feb 21;531:192–202. doi: 10.1016/j.virol.2019.02.011

Figure 5: Functional consequences of selected mutations in Nef.

Figure 5:

Mutations (S8R, W57Q, W57R, R71K and E108D) were introduced into the patient-derived Nef sequence SK329 (47.5% NFAT inhibition activity relative to SF2 Nef) and the Nef-mediated abilities to inhibit NFAT (A), down-regulate CD4 (B), down-regulate HLA-I (C) and down-regulate SERINC5 (D) were measured in triplicate. Activity relative to the wild-type SK329 (representing 100% activity) is shown. The ANOVA p value is shown and asterisks indicate significant differences between the mutants and the wild-type SK329: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). (E) Western blot analyses were used to assess the steady-state protein expression of Nef mutants. SF2 Nef and empty vector (ΔNef) were included as controls. Beta-actin protein was included as a cellular loading control.